AGENUS INC (AGEN) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 132.69M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $132.69M | (m) | (m) |
| 2026-03-31 | (m) | $123.87M | (m) | (m) |
| 2025-12-31 | (m) | $114.20M | (m) | (m) |
| 2025-09-30 | (m) | $106.83M | (m) | (m) |
| 2025-06-30 | (m) | $101.71M | (m) | (m) |
| 2025-03-31 | (m) | $99.52M | (m) | (m) |
| 2024-12-31 | (m) | $103.46M | (m) | (m) |
| 2024-09-30 | (m) | $160.43M | (m) | (m) |
| 2024-06-30 | (m) | $159.63M | (m) | (m) |
| 2024-03-31 | (m) | $161.42M | (m) | (m) |
| 2023-12-31 | (m) | $156.31M | (m) | (m) |
| 2023-09-30 | (m) | $100.90M | (m) | (m) |
| 2023-06-30 | (m) | $99.36M | (m) | (m) |
| 2023-03-31 | (m) | $94.98M | (m) | (m) |
| 2022-12-31 | (m) | $98.02M | (m) | (m) |
| 2022-09-30 | (m) | $89.90M | (m) | (m) |
| 2022-06-30 | (m) | $320.08M | (m) | (m) |
| 2022-03-31 | (m) | $309.89M | (m) | (m) |
| 2021-12-31 | (m) | $295.67M | (m) | (m) |
| 2021-09-30 | (m) | $306.67M | (m) | (m) |
| 2021-06-30 | (m) | $68.55M | (m) | (m) |
| 2021-03-31 | (m) | $84.76M | (m) | (m) |
| 2020-12-31 | (m) | $88.17M | (m) | (m) |
| 2020-09-30 | (m) | $91.41M | (m) | (m) |
| 2020-06-30 | (m) | $96.51M | (m) | (m) |
| 2020-03-31 | (m) | $85.28M | (m) | (m) |
| 2019-12-31 | (m) | $150.05M | (m) | (m) |
| 2019-09-30 | (m) | $122.00M | (m) | (m) |
| 2019-06-30 | (m) | $114.86M | (m) | (m) |
| 2019-03-31 | (m) | $115.04M | (m) | (m) |
| 2018-12-31 | (m) | $36.78M | (m) | (m) |
| 2018-09-30 | (m) | $38.69M | (m) | (m) |
| 2018-06-30 | (m) | $29.24M | (m) | (m) |
| 2018-03-31 | (m) | $17.56M | (m) | (m) |
| 2017-12-31 | (m) | $42.88M | (m) | (m) |
| 2017-09-30 | (m) | $40.10M | (m) | (m) |
| 2017-06-30 | (m) | $41.19M | (m) | (m) |
| 2017-03-31 | (m) | $43.57M | (m) | (m) |
| 2016-12-31 | (m) | $22.57M | (m) | (m) |
| 2016-09-30 | (m) | $24.64M | (m) | (m) |
| 2016-06-30 | (m) | $27.04M | (m) | (m) |
| 2016-03-31 | (m) | $26.82M | (m) | (m) |
| 2015-12-31 | (m) | $24.82M | (m) | (m) |
| 2015-09-30 | (m) | $18.80M | (m) | (m) |
| 2015-06-30 | (m) | $13.51M | (m) | (m) |
| 2015-03-31 | (m) | $10.21M | (m) | (m) |
| 2014-12-31 | (m) | $6.98M | (m) | (m) |
| 2014-09-30 | (m) | $5.75M | (m) | (m) |
| 2014-06-30 | (m) | $4.92M | (m) | (m) |
| 2014-03-31 | (m) | $2.66M | (m) | (m) |
| 2013-12-31 | (m) | $3.05M | (m) | (m) |
| 2013-09-30 | (m) | $3.74M | (m) | (m) |
| 2013-06-30 | (m) | $3.88M | (m) | (m) |
| 2013-03-31 | (m) | $3.70M | (m) | (m) |
| 2012-12-31 | (m) | $15.96M | (m) | (m) |
| 2012-09-30 | (m) | $15.51M | (m) | (m) |
| 2012-06-30 | (m) | $15.30M | (m) | (m) |
| 2012-03-31 | (m) | $15.46M | (m) | (m) |
| 2011-12-31 | (m) | $2.76M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $3.36M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $3.33M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |